Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...

InflaRx (IFRX) has released an update. InflaRx has received a positive opinion from the European Medicines Agency’s CHMP for GOHIBIC, a ...

Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...

Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...

If the European Commission decides to grant sales of the medicine, it will be the first Alzheimer's medicine available in the ...

InflaRx (IFRX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive ...

The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...

EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...